GlassScriptPhysician profile
Erika Herrera
NPI 1043716368
$6,128.69
in general payments reported to CMS, 2019-2025
36 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $1,118 · 2023: $1,505 · 2024: $1,828 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,778 · Education: $90.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,777.58 |
| Education | $90.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,015.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $628.79 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $581.52 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $559.79 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Pfizer INC. | $452.77 | 2021-2025 | |
| Amgen INC. | $374.13 | 2022-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $343.08 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $255.24 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $205.83 | 2021-2025 | |
| Dexcom, INC. | $188.33 | 2023-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.20 | 2023-2025 | Caplyta |
| Astellas Pharma US INC | $159.01 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $124.12 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $117.98 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $116.11 | 2024-2025 | Korlym |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.